Eighty patients will be included and randomized in two groups, one group (40 patients) will be administered 30 ml of the supplement Carminal, once a day, plus therapy for HP gastitis and the control group (40 patients) will be given standard therapy for HP gastritis with placebo. Treatment will begin after complection of upper endoscopy with histology results from biopted gastric mucosa. Treatment with Carminal will be continued after successful HP eradication during 12 weeks. The final evaluation will take place 12 weeks after the last Carminal intake, when control endoscopy with histology will be performed. The study will last approximately 24 weeks.
Patients aged 18 years or older
Patients with clinical symptoms of dyspepsia
Patients diagnosed with Helicobacter pylori positive gastritis, confirmed by upper endoscopy with histology
Patients who give written informed consent to participate in the study
Patients with peptic ulcer disease
Patients with previous gastric surgery
Patients with current malignancy or the history of any previous malignancies
Patients taking another investigational product, or have taken any investigational product in the last year